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Abstract: Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes. 
Both acute and chronically recurrent hypoglycemic events appear to have long-term consequences 
for patients with type 2 diabetes mellitus (T2DM). Chronically recurrent hypoglycemia may lead 
to an impairment of the counterregulatory system, with the potential for the development of hypo-
glycemia unawareness syndrome, increased severe hypoglycemia-associated hospitalization, and 
increased mortality. Hypoglycemic events may also have negative implications in cardiovascular 
disease and/or dementia. Avoidance of hypoglycemia by treating with appropriate, individualized 
regimens for patients with T2DM should be a primary focus of physicians. Utilizing traditional 
agents (eg, metformin and thiazolidinediones) that do not promote hypoglycemia, in combination 
with newer agents such as dipeptidyl peptidase-4 inhibitors and incretin mimetics, could offer 
a therapeutic advantage when trying to help patients reach their hemoglobin A1c goal without 
the added risk of hypoglycemia.
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Introduction
Hypoglycemia is a major barrier to care for physicians and their patients with 
type 2 diabetes mellitus (T2DM). Physicians and patients have attempted to minimize 
hypoglycemic episodes while managing blood glucose; however, for some patients the 
consequences of hypoglycemia extend beyond the classic signs and symptoms and may 
include increased mortality risk.1–3 Certain agents prescribed for T2DM significantly 
increase the risk of hypoglycemia; sulfonylureas and meglitinides are among these 
agents. Furthermore, some patients with diabetes mellitus may have a compromised 
hypoglycemic counterregulatory system, limiting self-awareness of a hypoglycemic 
attack, often called hypoglycemia unawareness syndrome.4,5 Recognizing risk factors 
for hypoglycemia and selecting an appropriate, patient-focused regimen are key steps 
in avoiding these life-  altering complications. The purpose of this paper is to offer 
suggestions for minimizing the risk of hypoglycemia utilizing currently available 
agents while still providing adequate blood glucose control.
Hypoglycemia
Signs, symptoms, and possible sequelae
Clinical hypoglycemia is characterized by Whipple’s triad, ie, signs and/or symptoms 
known or likely to be caused by hypoglycemia, a low plasma glucose level, and 
cessation of signs or symptoms after plasma glucose is raised.5 The signs and Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:3 50
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symptoms of hypoglycemia include those secondary to 
activation of the autonomic nervous system and neurogly-
copenia (Figure 1).6,7
The body’s defenses against hypoglycemia include 
decreased insulin secretion, increased glucagon secretion, 
and, when glucagon fails, increased serum epinephrine.5 In 
older patients and in patients who have a history of recurrent 
hypoglycemia, autonomic dysfunction can blunt or distort 
the response, making self-recognition of hypoglycemia more 
difficult. Hypoglycemia unawareness syndrome can delay a 
patient’s corrective behavioral action (ie, carbohydrate inges-
tion) and subsequently may cause confusion and an inability 
to correct the hypoglycemic state, possibly contributing to 
morbidity or mortality.4,5
Prevalence, morbidity, and mortality
Although morbidity and mortality attributable to 
hypoglycemia are less frequent in patients with T2DM 
than in those with type 1 diabetes, some T2DM patient 
populations (eg, those with advanced microvascular 
or macrovascular complications, extensive comorbid 
conditions, or long-standing diabetes mellitus) may exhibit 
a higher risk for morbidity and death from hypoglycemia.3 
Recently, in the Veterans Affairs Diabetes Trial, severe hypo-
glycemic events were demonstrated to be a strong predictor 
of a composite endpoint of cardiovascular disease (CVD) 
events and CVD mortality in intensively treated patients 
(hemoglobin A1c [HbA1c] goal  6%) and of all-cause mor-
tality in patients in the standard treatment arm.3
The Action to Control Cardiovascular Risk in Diabetes 
trial was stopped early when it was found that the total 
mortality rate due to any cardiovascular cause was 
significantly greater in the intensive treatment group versus 
the standard treatment group.1 It was hypothesized that the 
greater frequency of severe hypoglycemia in the intensively 
treated group compared with the standard treatment group 
(10.5% versus 3.5%, P  0.001) may have contributed to 
the excess mortality.2 Upon retrospective analysis of the data, 
researchers reported that severe hypoglycemia alone did not 
account for the difference in mortality between the two study 
groups.8 In fact, among patients who experienced an episode 
of severe hypoglycemia, the relative risk of death was lower in 
the intensive treatment group than in the standard arm, dem-
onstrating that patients with T2DM who experience symp-
tomatic, severe hypoglycemia are at increased risk of death 
regardless of intensity of glycemic control.8 Furthermore, a 
retrospective analysis showed patients with poorer glycemic 
control (higher baseline HbA1c) had a greater risk of hypogly-
cemia than patients with better glycemic control, regardless 
of treatment group.9 In the Action in Diabetes and Vascular 
Disease: Preterax and Diamicron Modified Release Con-
trolled Evaluation trial, the intensively treated group showed 
an increased incidence of hypoglycemia, compared with the 
standard group (2.7% versus 1.5%; hazard ratio [HR], 1.86; 
95% confidence interval [CI] 1.42–2.40; P  0.001).10 The 
findings of these outcomes trials further support the need for 
modifying patient therapy on the basis of individualized risks, 
including patients with increased risk for hypoglycemia and 
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Figure 1 Hypoglycemia: Critical point of care in diabetes management.7 Copyright  2006. Reprinted with permission from the American Diabetes Association, Briscoe VJ, Davis 
SN. Hypoglycemia in type 1 and type 2 diabetes: Physiology, pathophysiology and management. Clin Diabetes. 2006;24:115–121.
Notes: ammol/L × 18 = mg/dL; bCaused by falling glucose levels; cCaused by brain neuronal glucose deprivation.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:3 51
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selected populations where an aggressive glucose-lowering 
approach may not be appropriate.
Additionally, hypoglycemic events have been linked to 
an increased risk of morbidity and mortality in hospitalized 
patients, with or without T2DM. In ambulatory patients, 
Desouza et al reported an increased risk of cardiac ischemia 
during hypoglycemia.11 In a prospective, randomized trial 
of 1200 adult patients admitted to an intensive care unit, 
patients were divided into an intensive insulin treatment 
group (blood glucose maintained from 4.4 to 6.1 mmol/L 
[80 to 110 mg/dL]) and a standard care group (insulin 
therapy if blood glucose 11.9 mmol/L [215 mg/dL]).12 
Although intensive insulin therapy reduced morbidity, 
mortality was not reduced. Using regression analysis, 
hypoglycemia was identified as an independent risk factor 
for death in insulin-treated intensive care unit patients; 
the authors speculated that the associated hypoglycemia 
might have eliminated a significant mortality benefit in the 
intensive therapy group.12 On the other hand, Mellbin et al 
reported that hypoglycemia during hospitalization was not 
an independent predictor of future morbidity or mortality 
in cardiac patients with T2DM; however, hypoglycemia 
was more prevalent in high-risk patients (eg, those with 
long-standing T2DM).13
A recent retrospective cohort study assessed the occurrence 
of severe hypoglycemic events (requiring hospitalization) in 
T2DM patients (mean age 65 years) and potential associated 
risk of dementia later in life.14 Of the 16,000 T2DM patients 
from the Kaiser Permanente system, 8.8% had at least one 
episode of hypoglycemia. Patients with two episodes of 
severe hypoglycemia had an increased risk of dementia (HR, 
1.80; 95% CI 1.37–2.36). This study suggested a potentially 
modifiable mechanism of dementia. One underlying study 
limitation, however, was the use of electronic records rather 
than standardized assessments.14
Clinical recommendations
In their position statement on glycemic control and 
cardiovascular events on behalf of the American Diabetes 
Association, Skyler et al stated that issues associated with 
hypoglycemia unawareness could be particularly problematic 
for patients with coexisting autonomic neuropathy, which 
is a significant risk factor for sudden death.3 Consideration 
must be given to the benefit-risk ratio of intensive glucose 
control in certain high-risk patient groups.3 The strategy 
now recommended by various professional organizations is 
to aim for a target HbA1c  7% or 6.5% in most patients 
with T2DM but no history of CVD. Individualizing care 
is paramount, with less stringent targets recommended for 
patients with a long duration of T2DM, at high risk for severe 
hypoglycemia, and/or with multiple comorbidities.15,16 Age 
alone should not be the sole criterion for raising glycemic 
targets.
The American Association of Clinical Endocrinologists 
recommends that physicians encourage patients to achieve 
glycemic levels as near normal as possible, without inducing 
clinically significant hypoglycemia.16 Many of the current 
guidelines base their recommendations on drug profiles, 
including clinical efficacy and adverse events, in particular 
hypoglycemia risk.16,17
Drug therapy
There are several agents known to increase the risk of 
hypoglycemia (these include sulfonylureas, glinides, and 
insulin), whereas others (such as metformin, thiazolidinediones, 
glucagon-like peptide-1 [GLP-1] analogs, and dipeptidyl 
Table 1 Antihyperglycemic medications for type 2 diabetes mellitus18
Intervention Main effects Hypoglycemic risk
α-Glucosidase inhibitor Reduces rate of polysaccharide digestion in the proximal small intestine Low
Amylin agonist Slows gastric emptying and inhibits glucagon production Low
DPP-4 inhibitor Enhances effects of GLP-1 and GIP; increases glucose-mediated insulin secretion  
and suppresses glucagon secretion
Low
Glinide Stimulates insulin secretion Higha
GLP-1 agonist Potentiates glucose-stimulated insulin secretion Low
Insulin Insulin replacement High
Metformin Decreases hepatic glucose output Low
Sulfonylurea Enhances insulin secretion High
Thiazolidinedione Increases sensitivity of muscle, fat, and liver to endogenous and exogenous insulin Low
Notes: aMay be less frequent with nateglinide. 
Abbreviations: DPP-4, dipeptidyl peptidase-4; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:3 52
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peptidase-4 [DPP-4] inhibitors) are associated with a lower 
occurrence of hypoglycemia (Table 1).
Sulfonylureas enhance insulin secretion and are 
associated with hypoglycemia, especially in the elderly.18 
Chlorpropamide and glyburide are associated with more 
hypoglycemia than other agents in this class.18 Glinides 
increase insulin secretion and are also associated with 
hypoglycemia, although this may be less frequent than 
that seen with the sulfonylureas.18 Exogenous insulin 
preparations have all been associated with hypoglycemia, 
although the non-peaking and very short-acting analogs have 
demonstrated less of a risk.18
Metformin monotherapy, the recommended first-line 
therapy, is usually not associated with hypoglycemia; 
however, it is contraindicated with any condition that 
could increase the risk of lactic acidosis and in patients 
with increased serum creatinine (132.6 µmol/L 
[1.5 mg/dL], males; 123.8 µmol/L [1.4 mg/dL], females).18,19 
α-Glucosidase inhibitors slow the rate of polysaccharide 
digestion in the small intestine, and while less effective than 
other therapies, do not show evidence of hypoglycemia.18 
The thiazolidinediones, rosiglitazone and pioglitazone, as 
monotherapy do not increase the risk for hypoglycemia. 
Limitations with this class of agents, however, include 
increased fluid retention and congestive heart failure with 
both agents, and a possible increase in cardiovascular risk 
with rosiglitazone.18
Incretin-based therapies are composed of analogs to 
incretins and DPP-4 inhibitors. These agents increase insu-
lin secretion via a glucose-dependent mechanism. Exenatide 
is an incretin analog and binds to the glucagon-like peptide-
1 receptor in the pancreas to stimulate insulin secretion 
while slowing glucagon secretion. While exenatide has 
not been associated with hypoglycemia, gastrointestinal 
side effects, nausea, and its injectable route of adminis-
tration may limit its usefulness.18 Long-acting formula-
tions have demonstrated significantly less nausea.20 Two 
dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin and 
saxagliptin) are approved in the US and inhibit the enzyme 
that metabolizes endogenous glucagon-like peptide-1; thus, 
this hormone has a more prolonged effect on postprandial 
glucose through its effects on insulin secretion and suppres-
sion of glucagon secretion. DPP-4 inhibitor monotherapy 
minimizes the potential for hypoglycemia.18 Due to this 
low propensity for hypoglycemia, the National Institute for 
Health and Clinical Excellence stated a preference for DPP-
4 inhibitors as second-line therapy versus sulfonylureas in 
patients at risk for hypoglycemia.17
Conclusions
Hypoglycemia can be a limiting factor in the management 
of T2DM and may increase cardiovascular risk in addition 
to other possible acute and long-term detrimental effects. 
A therapeutic HbA1c target of  7% should be maintained, 
but needs to be individualized based on patient characteristics 
for an appropriate benefit-risk ratio. Medications such 
as metformin, DPP-4 inhibitors, thiazolidinediones, and 
injectable incretin analogs are efficacious with a low risk of 
hypoglycemia, and offer an important therapeutic advantage 
in minimizing hypoglycemic events.
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